Patents by Inventor Bruce L. Levine

Bruce L. Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
    Patent number: 11896614
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 13, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: David M. Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Nathan Amar Singh, Zoe Zheng
  • ICOS CRITICALLY REGULATES THE EXPANSION AND FUNCTION OF INFLAMMATORY HUMAN TH17 CELLS
    Publication number: 20230399615
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: March 3, 2023
    Publication date: December 14, 2023
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Publication number: 20230302052
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 28, 2023
    Inventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20230295296
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 21, 2023
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Methods for treating chronic lymphocytic leukemia (CLL)
    Patent number: 11648270
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: May 16, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
  • COMPOSITIONS AND METHODS FOR REGULATING CAR T CELLS
    Publication number: 20230034117
    Abstract: The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell.
    Type: Application
    Filed: May 3, 2022
    Publication date: February 2, 2023
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Saar Gill
  • Toxicity Management for Anti-Tumor Activity of CARs
    Publication number: 20230013642
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CART cell in the patient.
    Type: Application
    Filed: February 22, 2022
    Publication date: January 19, 2023
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • Toxicity management for anti-tumor activity of CARs
    Patent number: 11273219
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CART cell in the patient.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: March 15, 2022
    Assignees: The Trustees of the University of Pennsylvania, The Children's Hospital of Philadelphia
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS
    Publication number: 20210246423
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: September 18, 2020
    Publication date: August 12, 2021
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • ICOS critically regulates the expansion and function of inflammatory human Th17 cells
    Patent number: 11001805
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 11, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Methods for improving the efficacy and expansion of immune cells
    Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Toxicity management for anti-tumor activity of CARs
    Patent number: 10603378
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: March 31, 2020
    Assignees: The Trustees of the University of Pennsylvania, The Children's Hospital of Philadelphia
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • Compositions and Methods for Regulating CAR T Cells
    Publication number: 20190367610
    Abstract: The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell.
    Type: Application
    Filed: December 11, 2018
    Publication date: December 5, 2019
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Saar Gill
  • METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Publication number: 20190336530
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Application
    Filed: March 8, 2019
    Publication date: November 7, 2019
    Inventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR - EXPRESSING CELLS
    Publication number: 20190292257
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Zoe Zheng
  • Methods of making chimeric antigen receptor-expressing cells
    Patent number: 10273300
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 30, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells
    Publication number: 20180371414
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: May 22, 2018
    Publication date: December 27, 2018
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • USE OF CART19 TO DEPLETE NORMAL B CELLS TO INDUCE TOLERANCE
    Publication number: 20180271907
    Abstract: The present invention provides compositions and methods for inducing tolerance in a human. The invention includes administering a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: June 4, 2018
    Publication date: September 27, 2018
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Toxicity Management for Anti-Tumor Activity of CARs
    Publication number: 20180256712
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
    Type: Application
    Filed: May 7, 2018
    Publication date: September 13, 2018
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • Compositions and Methods for Treatment of Cancer
    Publication number: 20180258391
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: September 6, 2017
    Publication date: September 13, 2018
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone